Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.969633
Keywords
Treg; regulatory T cell; transplantation; costimulation blockade; CTLA4 Ig; IL-2; immunosuppressant; costimulation
Categories
Funding
- Medical-Scientific Fund of the Major of Vienna [21050]
- Vienna Science and Technology Fund [LS18-031]
- Country of Lower Austria Danube Allergy Research Cluster (DARC)
Ask authors/readers for more resources
Regulatory T cells (Tregs) play a critical role in transplantation, and the use of pharmaceutical costimulation blockers may have an impact on these cells. This review provides an overview of the effects of costimulation therapy on Treg function.
Regulatory T cells (Tregs) play a critical role in maintaining self-tolerance and in containing allo-immune responses in the context of transplantation. Recent advances yielded the approval of the first pharmaceutical costimulation blockers (abatacept and belatacept), with more of them in the pipeline. These costimulation blockers inhibit effector cells with high clinical efficacy to control disease activity, but might inadvertently also affect Tregs. Treg homeostasis is controlled by a complex network of costimulatory and coinhibitory signals, including CD28, the main target of abatacept/belatacept, and CTLA4, PD-1 and ICOS. This review shall give an overview on what effects the therapeutic manipulation of costimulation has on Treg function in transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
